These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10077031)

  • 1. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function.
    Swan SK; Baker JF; Free R; Tucker RM; Barron B; Barr R; Seltzer S; Gazelle GS; Maravilla KR; Barr W; Stevens GR; Lambrecht LJ; Pierro JA
    J Magn Reson Imaging; 1999 Feb; 9(2):317-21. PubMed ID: 10077031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial.
    Rubin DL; Desser TS; Semelka R; Brown J; Nghiem HV; Stevens WR; Bluemke D; Nelson R; Fultz P; Reimer P; Ho V; Kristy RM; Pierro JA
    J Magn Reson Imaging; 1999 Feb; 9(2):240-50. PubMed ID: 10077020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment.
    Swan SK; Lambrecht LJ; Townsend R; Davies BE; McCloud S; Parker JR; Bensel K; LaFrance ND
    Invest Radiol; 1999 Jul; 34(7):443-8. PubMed ID: 10399633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pediatric subjects.
    Baker JF; Kratz LC; Stevens GR; Wible JH
    Invest Radiol; 2004 Jun; 39(6):334-9. PubMed ID: 15167099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients.
    Lowe LH; Kearns GL; Wible JH
    Curr Med Res Opin; 2006 Dec; 22(12):2515-24. PubMed ID: 17166334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers.
    Staks T; Schuhmann-Giampieri G; Frenzel T; Weinmann HJ; Lange L; Platzek J
    Invest Radiol; 1994 Jul; 29(7):709-15. PubMed ID: 7960618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function.
    Davies BE; Kirchin MA; Bensel K; Lorusso V; Davies A; Parker JR; Lafrance ND
    Invest Radiol; 2002 May; 37(5):299-308. PubMed ID: 11979156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The OptiMARK clinical development program: summary of safety data.
    Brown JJ; Kristy RM; Stevens GR; Pierro JA
    J Magn Reson Imaging; 2002 Apr; 15(4):446-55. PubMed ID: 11948834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients.
    Wible JH; Tata PN; Napoli AM; Lowe LH; Kearns GL
    Magn Reson Imaging; 2009 May; 27(4):512-8. PubMed ID: 18814985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the safety of standard and triple dose gadodiamide injection in MR imaging of the central nervous system. A double-blind study.
    Svaland MG; Christensen T; Lundorf E
    Acta Radiol; 1994 Jul; 35(4):396-9. PubMed ID: 8011392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety assessment of gadoversetamide (OptiMARK) administered by power injector.
    Abdou N; Napoli AM; Hynes MR; Allen JC; Wible JH
    J Magn Reson Imaging; 2004 Jan; 19(1):133-40. PubMed ID: 14696230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the safety of the standard dose and a higher dose of gadodiamide injection for MR imaging of the central nervous system.
    Svaland MG; Lundby B; Kristoffersen DT
    J Magn Reson Imaging; 1994; 4(3):419-23. PubMed ID: 8061442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
    Runge VM
    Invest Radiol; 2017 Jun; 52(6):317-323. PubMed ID: 28368880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system.
    Oudkerk M; Sijens PE; Van Beek EJ; Kuijpers TJ
    Invest Radiol; 1995 Feb; 30(2):75-8. PubMed ID: 7782190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA.
    Akeson P; Jonsson E; Haugen I; Holtås S
    Neuroradiology; 1995 Apr; 37(3):229-33. PubMed ID: 7603600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
    Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
    Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA).
    Grossman RI; Rubin DL; Hunter G; Haughton VM; Lee D; Sze G; Kuhn MJ; Maravilla K; Tu R; Heindel W; Wippold FJ; Leeds N; Zelch J; Jinkins JR; Grodd W; Truwit C; Kanal E; Provenzale JM; Ramsey R; Simon J; Brunberg JA; Stevens GR; Kristy RM
    Invest Radiol; 2000 Jul; 35(7):412-9. PubMed ID: 10901102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of p792, a new blood-pool agent: results of clinical testing in nonpatient volunteers.
    Gaillard S; Kubiak C; Stolz C; Bonnemain B; Chassard D
    Invest Radiol; 2002 Apr; 37(4):161-6. PubMed ID: 11923638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans.
    Schuhmann-Giampieri G; Mahler M; Röll G; Maibauer R; Schmitz S
    J Clin Pharmacol; 1997 Jul; 37(7):587-96. PubMed ID: 9243351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.